[ADA] Inventage 안전 바카라사이트 long-acting GLP-1 injectable and oral formulation technology draws global interest

[by Kang, In Hyo] 안전 바카라사이트 Lab, a company specializing in drug delivery technology platforms, announced on June 24 that it participated in the American Diabetes Association (ADA 2025) Annual Meeting, held in Chicago, USA, from June 20 to 23 (local time). During the conference, the company presented its next-generation obesity treatment platform technology in a poster session.

In this presentation, 안전 바카라사이트 Lab introduced preclinical data on its pipeline of long-acting and oral formulations (IVL3021 and IVL3024), a once-monthly injectable candidate based on semaglutide and tirzepatide, as well as an oral formulation of semaglutide (IVL3027).

According to the presentation, Inventage Lab’s long-acting injection formulations, developed using the company’s proprietary ‘microsphere’ technology, demonstrated notable advantages such as excellent particle size uniformity and effective suppression of the initial burst release phenomenon, features that contribute to stable and sustained drug delivery. Additionally, the oral semaglutide candidate ‘IVL3027’ garnered significant interest from conference attendees due to its markedly improved bioavailability over existing oral formulations and its ability to maintain drug release for up to one week.

According to the company, numerous global pharmaceutical companies, including Novo Nordisk, Amgen, Regeneron, and Madrigal Pharmaceuticals, visited Inventage Lab’s poster session and expressed strong interest. These companies highly regarded the absence of initial release in Inventage Lab’s long-acting injectable formulations, recognizing it as a key feature that could enhance competitiveness in real-world clinical settings. Furthermore, Inventage Lab’s long-acting injectable and oral drug delivery platforms were evaluated as promising solutions capable of addressing key limitations of existing glucagon-like peptide 1 (GLP-1) therapies, particularly in terms of patient compliance and high cost structure.

Building on the strong interest observed at both the 2025 ‘BIO USA,’ held last week in Boston, USA, and the ADA Annual Meeting, Inventage Lab announced plans to actively pursue discussions on global technology transfer and co-development collaborations. Prior to participating in ADA, the company operated a standalone booth at BIO USA, where it conducted follow-up meetings with Novo Nordisk and held partnership discussions with Genentech, AbbVie, Sanofi, Roche, and Leo Pharma.

Inventage Lab intends to reinforce its strategic partnerships in key markets, including the United States and Europe, and to advance the global commercialization roadmap for its pipeline based on the company’s proprietary platform technologies, ‘IVL-DrugFluidic’ and ‘IVL-PePOFluidic.’